Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bridging studies in clinical development.

Jen-pei Liu1, Shein-Chung Chow

  • 1Department of Statistics, National Cheng-Kung University, Tainan, Taiwan. jpliu@nhri.org.tw

Journal of Biopharmaceutical Statistics
|November 27, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The pyruvate kinase activator etavopivat (FT-4202) limits pulmonary and systemic sequelae of sepsis in a mouse LPS model.

American journal of physiology. Lung cellular and molecular physiology·2026
Same author

Power Calculation for Non-inferiority Test Based on Linear Combination of Two Correlated Binary Endpoints.

Therapeutic innovation & regulatory science·2026
Same author

Controversial issues in clinical investigation of rare disease drug development.

Journal of biopharmaceutical statistics·2026
Same author

Switching Design for Assessment of Interchangeability in Biosimilar Studies.

Pharmaceutics·2026
Same author

Acupuncture for acute musculoskeletal pain in the emergency department and clinic: a pragmatic randomized trial.

Pain medicine (Malden, Mass.)·2025
Same author

Study Protocol: Single-Blinded, Controlled, Clinical Trial Evaluating the Feasibility of Spinal Cord Stimulation for Improving Neuropathic Pain and Rehabilitation Outcomes in Patients With Thoracic Spinal Cord Injury.

Neurosurgery practice·2025
Same journal

Correction.

Journal of biopharmaceutical statistics·2026
Same journal

Leveraging external controls in clinical trials: estimands, estimation, assumptions.

Journal of biopharmaceutical statistics·2026
Same journal

Special issue of nonclinical statistics in regulatory applications guest editors' notes.

Journal of biopharmaceutical statistics·2026
Same journal

Comparison of flexible parametric modeling and nonparametric methods to estimate restricted mean survival time: A simulation study.

Journal of biopharmaceutical statistics·2026
Same journal

Simulated treatment comparisons with jackknife pseudo values for estimating population-adjusted marginal treatment effects.

Journal of biopharmaceutical statistics·2026
Same journal

Sample sizes for randomized controlled trials utilizing Bayesian response adaptive randomization for continuous outcomes.

Journal of biopharmaceutical statistics·2026
See all related articles

Understanding ethnic factors is vital for global pharmaceutical development. The ICH E5 guideline helps assess how regional differences impact drug efficacy and safety, guiding necessary bridging studies.

Area of Science:

  • Pharmacogenomics and Global Drug Development
  • Regulatory Science and International Harmonization

Background:

  • Global pharmaceutical development necessitates understanding ethnic variations in drug efficacy and safety.
  • Geotherapeutics and regulatory bodies increasingly focus on regional differences in clinical data acceptability.

Purpose of the Study:

  • To provide an overview of the International Conference on Harmonization (ICH) E5 guideline on ethnic factors.
  • To explain the framework for evaluating the impact of ethnic variations on pharmaceutical products.

Main Methods:

  • Discussion of ethnic sensitivity and the necessity of bridging studies.
  • Categorization of different types of bridging studies.
  • Outline of methods for assessing regional similarity using bridging evidence.

Related Experiment Videos

Main Results:

  • The ICH E5 guideline offers a framework for assessing ethnic impacts on drug efficacy, safety, dosage, and regimen.
  • Bridging studies are essential for evaluating foreign clinical data acceptability across regions.
  • Challenges exist in establishing regulatory requirements and assessing bridging evidence.

Conclusions:

  • The ICH E5 guideline is crucial for global pharmaceutical sponsors navigating ethnic variations.
  • Effective design and analysis of bridging studies are key to regulatory acceptance.
  • Addressing regulatory and methodological challenges is vital for successful international drug development.